Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, Belgium.
Institute of Tropical Medicine, Antwerp, Belgium; Clinical Virology Unit, Institute of Tropical Medicine, Antwerp, Belgium.
Clin Chim Acta. 2022 Jun 1;531:4-11. doi: 10.1016/j.cca.2022.03.005. Epub 2022 Mar 10.
COVID-19 patients experience several features of dysregulated immune system observed in sepsis. We previously showed a dysregulation of several proline-selective peptidases such as dipeptidyl peptidase 4 (DPP4), fibroblast activation protein alpha (FAP), prolyl oligopeptidase (PREP) and prolylcarboxypeptidase (PRCP) in sepsis. In this study, we investigated whether these peptidases are similarly dysregulated in hospitalized COVID-19 patients.
Fifty-six hospitalized COVID-19 patients and 32 healthy controls were included. Enzymatic activities of DPP4, FAP, PREP and PRCP were measured in samples collected shortly after hospital admission and in longitudinal follow-up samples.
Compared to healthy controls, both DPP4 and FAP activities were significantly lower in COVID-19 patients at hospital admission and FAP activity further decreased significantly in the first week of hospitalization. While PRCP activity remained unchanged, PREP activity was significantly increased in COVID-19 patients at hospitalization and further increased during hospital stay and stayed elevated until the day of discharge.
The changes in activities of proline-selective peptidases in plasma are very similar in COVID-19 and septic shock patients. The pronounced decrease in FAP activity deserves further investigation, both from a pathophysiological viewpoint and as its utility as a part of a biomarker panel.
COVID-19 患者表现出几种免疫系统失调的特征,这些特征在脓毒症中也观察到过。我们之前曾显示,在脓毒症中几种脯氨酸选择性肽酶(如二肽基肽酶 4(DPP4)、成纤维细胞激活蛋白 α(FAP)、脯氨酰寡肽酶(PREP)和脯氨酰羧肽酶(PRCP))失调。在这项研究中,我们研究了这些肽酶是否在住院 COVID-19 患者中同样失调。
纳入 56 名住院 COVID-19 患者和 32 名健康对照者。在入院后不久采集样本并进行纵向随访样本,测量 DPP4、FAP、PREP 和 PRCP 的酶活性。
与健康对照组相比,COVID-19 患者入院时 DPP4 和 FAP 活性均显著降低,且 FAP 活性在入院后第一周进一步显著降低。PRCP 活性保持不变,而 PREP 活性在 COVID-19 患者入院时显著升高,并在住院期间进一步升高,直至出院日仍保持升高。
COVID-19 患者和脓毒性休克患者血浆中脯氨酸选择性肽酶活性的变化非常相似。FAP 活性的明显下降值得进一步研究,既从病理生理学的角度,也从其作为生物标志物组分之一的实用性角度。